Management of Parkinson׳s disease: Current and future pharmacotherapy
- PMID: 25637088
- DOI: 10.1016/j.ejphar.2015.01.030
Management of Parkinson׳s disease: Current and future pharmacotherapy
Abstract
Parkinson׳s disease (PD) is chronic progressive neurodegenerative disorder characterized by profound loss of dopaminergic neurons in the nigrostriatal pathway. It is recognized by the cardinal clinical features of bradykinesia, rigidity, tremor and postural instability. Current therapeutic options are primarily dopamine replacement strategies that only provide symptomatic improvement without affecting progressive neuronal loss. These treatments often fail to provide sustained clinical benefit and most patients develop motor fluctuations and dyskinesias as the disease progresses. Additionally, non-motor symptoms such as autonomic disturbances, sensory alterations, olfactory dysfunction, mood disorders, sleep disturbances and cognitive impairment cause considerable functional disability in these patients and these features often fail to respond to standard dopaminergic treatments. This mini review outlines the current pharmacotherapeutic options for PD and highlights the emerging experimental therapies in various phases of clinical development.
Keywords: Adenosine receptor antagonist; Levodopa induced dyskinesia; Parkinson׳s disease; Safinamide.
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
-
Safinamide for the treatment of Parkinson's disease.Expert Rev Clin Pharmacol. 2014 Nov;7(6):747-59. doi: 10.1586/17512433.2014.968555. Epub 2014 Oct 10. Expert Rev Clin Pharmacol. 2014. PMID: 25300164 Review.
-
Safinamide in the treatment of Parkinson's disease.Expert Opin Pharmacother. 2010 Sep;11(13):2261-8. doi: 10.1517/14656566.2010.511612. Expert Opin Pharmacother. 2010. PMID: 20707760 Review.
-
Safinamide: a new hope for Parkinson's disease?Drug Discov Today. 2018 Mar;23(3):736-744. doi: 10.1016/j.drudis.2018.01.033. Epub 2018 Jan 12. Drug Discov Today. 2018. PMID: 29339106 Review.
-
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.Mov Disord. 2014 Sep;29(10):1273-80. doi: 10.1002/mds.25961. Epub 2014 Jul 10. Mov Disord. 2014. PMID: 25044402 Clinical Trial.
-
Safinamide for the treatment of Parkinson's disease.Expert Opin Investig Drugs. 2014 May;23(5):729-42. doi: 10.1517/13543784.2014.897694. Epub 2014 Mar 21. Expert Opin Investig Drugs. 2014. PMID: 24650154 Review.
Cited by
-
A New Stereoselective Approach to the Substitution of Allyl Hydroxy Group in para-Mentha-1,2-diol in the Search for New Antiparkinsonian Agents.Molecules. 2023 Oct 27;28(21):7303. doi: 10.3390/molecules28217303. Molecules. 2023. PMID: 37959723 Free PMC article.
-
Molecular docking/dynamics simulations, MEP analysis, bioisosteric replacement and ADME/T prediction for identification of dual targets inhibitors of Parkinson's disease with novel scaffold.In Silico Pharmacol. 2023 Jan 19;11(1):3. doi: 10.1007/s40203-023-00139-3. eCollection 2023. In Silico Pharmacol. 2023. PMID: 36687301 Free PMC article.
-
Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease.PLoS One. 2018 Mar 1;13(3):e0192121. doi: 10.1371/journal.pone.0192121. eCollection 2018. PLoS One. 2018. PMID: 29494603 Free PMC article.
-
Recent Status of Nanomaterial Fabrication and Their Potential Applications in Neurological Disease Management.Nanoscale Res Lett. 2018 Aug 10;13(1):231. doi: 10.1186/s11671-018-2638-7. Nanoscale Res Lett. 2018. PMID: 30097809 Free PMC article. Review.
-
Glycomic and Proteomic Changes in Aging Brain Nigrostriatal Pathway.Mol Cell Proteomics. 2018 Sep;17(9):1778-1787. doi: 10.1074/mcp.RA118.000680. Epub 2018 Jun 18. Mol Cell Proteomics. 2018. PMID: 29915149 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
